Erman Akkus: ESMO-2023, hepatobiliary and pancreatic cancers
Erman Akkus, Medical Oncology Fellow at Ankara University, shared on X/Twitter:
“ESMO-2023, hepatobiliary and pancreatic cancers ESMO – Eur. Oncology, EORTC
-Biliary tract cancers
Outcomes worse in extraheoatic CCA than intrahepatic with cis-gem.
tinengotinib as a FGFR2 inhibitor after progression with another FGFR inhibitor.
DESTINY-PanTumor02 trial, trastuzumab deruxtecan in second line for HER-2 positive BTC.
-HCC
AdvanTIG-206 trial, Adding ociperlimab (anti-TIGIT) to tislelizumab (anti-PD1) plus BAT1706 (anti-VEGF) > negative study.
-Pancreatic cancer
GENERATE trial, gemcitabine nab-paclitaxel vs mFOLFIRINOX or S-IROX > favoring gem-nabpacli in Asian population.
PREOPANC-2 trial, neoadjuvant FOLFIRINOX vs Gemcitabine-radiotheraphy in borderline resectable and resectable cancers > no differences.”
Visit the article website.
Source: Erman Akkus/X